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ABSTRACT

Loss of the Lipopolysaccharide Core Biosynthesis rfaD Gene Increases Antimicrobial
Chemokine Binding and Bacterial Susceptibility to CCL28 and Polymyxin:
A Model for Understanding the Interface of Antimicrobial Chemokines
and Bacterial Host Defense Avoidance Mechanisms
Cynthia Lew
Department of Microbiology and Molecular Biology, BYU
Master of Science

In order to better understand the mechanism of antimicrobial chemokine activity,
including binding to and killing of bacteria, random transposon mutagenesis was
performed in Yersinia pseudotuberculosis. Resulting mutants were screened for increased
binding to chemokine and high binding clones were selected for further study. One
mutant, designated mutant 27, was found to have a single insertion mutation in the rfaD
gene. The rfaD gene product is involved in heptose biosynthesis, one of the sugars of
the inner core oligosaccharide of Gram‐ negative lipopolysaccharide (LPS). Mutant 27
was found to bind both CCL25 and CCL28, two antimicrobial chemokines, more
efficiently than the wild type bacteria. This clone was also found to be more susceptible
to CCL28‐ mediated killing and polymyxin activity. Complementation with a plasmid
bearing the full rfaDFC operon restored the wild type phenotype in both regards. These
data suggest that normal LPS expression by Y. pseudotuberculosis serves to protect the
bacteria from the antimicrobial function of chemokines and other antimicrobial proteins
of the mammalian innate immune system.
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INTRODUCTION

1.

Immune system

The human immune system is divided into two separate but closely interacting
branches: natural, or innate immunity, and adaptive, or acquired immunity. The innate
immune response is uniform throughout a whole species and similar elements or
components are conserved even among vastly different species (e.g. leucine rich
receptors (LRRs) in humans and flies) or kingdoms (e.g. RNA interference in plants and
animals). Conversely, adaptive immunity seems to be characteristic to vertebrates only
[1‐3].

1.1

Innate Immunity

The innate immune response is faster reacting than the adaptive response but is
less specific and relies primarily on physical, chemical, and cellular barriers. Physical
barriers include the skin, the mucosal membranes of internal epithelia and the
movement of cilia in the lungs. Other important components are soluble factors, such as
proteins with antimicrobial activity (called antimicrobial peptides or, alternately, host
defense peptides). Examples of these include lysozyme or defensins. Chemical barriers
include stomach acid or bile salts. Leukocytes involved in the innate immune response
are phagocytic cells, including blood monocytes, neutrophils and macrophages.
Granulocytic neutrophils are generally the first cells at the site of infection and release a
1

variety of antimicrobial agents, many of which are antimicrobial peptides [4, 5].
Activated macrophages have increased phagocytic abilities and also secrete
inflammatory mediators.

The innate immune system responds directly to pathogen invasion [6] using a
variety of soluble factors and receptors. Due to the ancient roots and conservation of
innate immune mechanisms in the animal kingdom, it is anticipated that the signals
recognized would also be conserved by pathogens [7]. These conserved features are
known as pathogen‐ associated molecular patterns (PAMPs). For example, the
complement cascade can be triggered by recognition of bacterial or viral PAMPs
including lipopolysaccharide (LPS), peptidoglycan, or viral protein coats. Complement
activation leads to bacterial death via the formation of pores in the membrane (via the
membrane attack complex). In addition to complement, pattern recognition receptors
(PRRs), such as Toll‐ like receptors (TLRs) or Nod proteins recognize specific microbial
ligands and initiate a signal transduction pathway that leads to cytokine production
and other immune responses. These ligands may include bacterial LPS, peptidoglycan,
dsRNA, ssDNA, and CpG unmethylated dinucleotide repeats, or other danger signals
(sometimes called danger‐ associated molecular patterns (DAMPs)).

Both soluble factors and receptors play an important role in the actual innate
immune response and in activating the adaptive immune response. Responses through
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TLRs can increase cytokine production and lead to inflammation. Inflammation is
important in pathogen clearance and in the activation of healing and rebuilding
processes. Inflammation helps localize immune cells to the site of infection. Classical
signs of inflammation are localized increases in redness, heat, swelling, pain, and loss of
function. Complement connects the innate and adaptive immune responses through the
complement fragments remaining after enzymatic cleavage (e.g. C3a or C5a). These are
known as anaphylatoxins and can induce degranulation of mast cells and basophils as
well as contribute to inflammation by increasing vascular permeability and inducing
smooth muscle contraction [8]. Anaphylatoxins also act as chemoattractant signals [9] to
further recruit immune cells, including helper T cells, an essential component of the
adaptive immune response, helping contribute to the inflammatory response.

1.2

Adaptive Immunity

The adaptive immune response takes time to generate but the resulting response
is specific and provides memory. The adaptive immune system responds in an antigen
specific way to a wide variety of microbes, even those not previously encountered.
Because of this specificity, it takes longer for the antigen to be found by its ideal
(strongest) binding partner and for the proper response to develop. However, because
of the memory capabilities of the adaptive immune response, the secondary response—
the response developed after re‐ exposure to the same antigen—is much faster than the
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primary response. The adaptive immune response includes the humoral response and
the cell‐ mediated response.

The humoral response consists of antibodies that specifically recognize a
particular antigen. Upon recognition of its antigen, the B cell expressing that antibody
will clonally expand, producing both plasma cells, which continue to make antibodies
with the same specificity, and memory cells, which retain their specificity but are not
actively producing antibody. Upon re‐ exposure to the same antigen, these memory
cells can be activated much quicker and produce the specific antibodies. In order to
become fully active, B cells need CD4 T helper cells, which release cytokines that
stimulate proliferation and promote class switching [10]. These are usually Th2 cells.
The Th1 subset of CD4 T cells stimulates the cell‐ mediated response.

The effector cells of the cell‐ mediated adaptive immune response are cytotoxic T
lymphocytes (CTLs). CTLs have T‐ cell receptors (TCRs) that recognize antigen
presented by MHC class I molecules. Similar to B cells, upon specific binding CTLs will
undergo clonal expansion, resulting in CTLs with the same antigen‐ specific TCR. CTLs
kill by releasing perforins, which form holes in the microbial membrane [11] and
granzymes, serine proteases that induce apoptosis [12]. They can also induce apoptosis
via the Fas‐ FasL pathway. A subset of CTLs will also become memory cells that can be
reactivated upon secondary exposure to antigen.
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1.3

Cytokines and Cytokine Signaling

The innate and adaptive branches are connected through small signal molecules,
known as cytokines. Immune cells of both branches produce and secrete cytokines in
response to recognition of conserved sequences on pathogens by innate immune cells or
antigen recognition by B or T cells.

Most cytokines can be grouped into one of six families based on structure and
activity, and each family has a specific receptor type that recognizes it. Cytokines
known as interleukins are responsible for cell‐ to‐ cell cytokine signaling. Cytokine
signaling takes place in either an autocrine or paracrine fashion, allowing infected cells
to upregulate their own defenses as well as warn neighboring cells. These cytokines
may have pro‐ or anti‐ inflammatory effects, help in B and T cell activation, induce
antibody class switching, or activate macrophages, eosinophils and mast cells. Binding
of a cytokine to its reciprocal receptor triggers an intracellular signaling cascade that
leads to activation or regulation of transcription. Another major subset of cytokines, a
group of proteins called chemokines, is involved specifically in cell migration in a
process known as chemotaxis.

2.

Chemokines

Chemokines are cytokines that mediate chemotaxis, or cellular movement
towards or away from a certain stimulus or signal. They are a superfamily of 8‐ 16kDa
5

proteins that share 20‐ 70% homology in their amino acid sequences. As signal
molecules, chemokines have at least two different functions, often classified accordingly
as homeostatic or inflammatory. Homeostatic chemokines are constitutively expressed
and direct cells into and through lymphoid tissues and organs [13, 14], including bone
marrow, spleen, thymus and lymph nodes. They also direct cells to mucosal tissues and
the skin—surfaces that have contact with the outside environment [15]. These
homeostatic chemokines have been found in blood, lymph nodes, sweat, saliva, milk,
and tears (exocrine secretions) [15]. The inflammatory chemokines are inducible
chemokines that attract immune cells to the site of infection. These chemokines are
upregulated in response to immune stimuli, such as viral or bacterial infection [16]. The
chemokines and receptors expressed by various cells affect the types of cells attracted to
a specific site.

Chemokines are divided into the following four families, based on their amino
acid sequence (specifically the spacing between the first two cysteine residues) and the
immune cells they attract: CXC, CC, C and CXXXC [17]. Chemokines of the CXC and
CC families are most common, but there are two examples of C chemokines and one
example of CXXXC chemokines known. Almost all chemokines have four conserved
cysteine residues (except for the C group) whose disulfide bonds help stabilize the
Greek key structure common to the family (four adjacent anti‐ parallel β sheets
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connected by two small hairpins and one longer loop) [18‐21]. Chemokine
nomenclature was standardized by Zlotnik and Yoshie in 2000 [16].

Chemokines have been shown to oligomerize, forming mostly homodimers.
However, whether or not chemokines act as dimers is still uncertain. Chemokines can
bind as monomers and it has been shown that the concentrations required for
dimerization are lower than the concentrations found in vivo for optimal chemokine
activity [21]. Additionally, even if dimerization does occur, it may not be essential for
receptor binding and activation, as a mutant of monocyte chemoattractant protein‐ 1
(MCP‐ 1) without the ability to dimerize still showed wild type binding affinity and
stimulatory activity [22].

Chemokine gradients are sensed by cell receptors and guide immune cells to the
specific site of infection. Many of the cleavage products in the complement cascade
(anaphylatoxins) also have chemotactic properties (C4a, C3a and C5a) [23]. Immune
cells migrate up the concentration gradient, meaning they move towards the source of
chemokine production as the concentration of chemokine increases. Different classes of
human leukocytes have different chemokine receptor expression profiles.

2.1

Chemokine receptors

Chemokine receptors are seven transmembrane G‐ protein coupled receptors
located on cell surfaces [24]. There are at least 18 chemokine receptors known and they
7

can be divided into classes that correspond to the class of chemokine that binds them
[25]. Chemokine receptor‐ ligand binding is both specific and redundant, meaning one
receptor can recognize multiple chemokines and that chemokines can have multiple
cognate receptors. Binding of a chemokine to its receptor initiates a calcium dependent
signal transduction pathway within the cell leading to upregulation of actin
polymerization, adhesion, and cytoskeletal rearrangement—all modifications that are
involved in chemotaxis.

3.

Antimicrobial peptides

Antimicrobial peptides are important components of the innate immune
response. They have an overall positive net charge, which is thought to allow them to
interact, through electrostatic attraction, with the usually negatively‐ charged bacterial
membranes (due to the lipid A of Gram‐ negative bacteria or the teichoic acids of Gram‐
positive bacteria) [26]. Of the more than 800 antimicrobial peptides found thus far, most
are fairly small in size [27, 28]. Antimicrobial peptides are ancient mechanisms of
defense and have a broad range of activity. Various antimicrobial peptides have been
shown to have activity against both Gram‐ negative and Gram‐ positive bacteria, acid
fast bacteria, fungi, parasites and even some viruses (for examples see [29‐34]). As
components of the innate immune system, antimicrobial peptides are a well conserved
defense mechanism and have been found in numerous organisms of different kingdoms
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and species, including humans, fish, plants, insects and others [35‐38]. Antimicrobial
peptides are rapidly expressed at the site of infection or damage. They can either be
synthesized de novo or deposited at the site by some cell, usually an immune cell such as
a neutrophil [39]. While not normally expressed at high levels, antimicrobial peptides
can be upregulated or induced leading to an increased concentration at the site of an
infection.

3.1

Mechanism and activity

There are many proposed mechanisms for antimicrobial peptide activity, many
of which include membrane permeabilization via the formation of a pore, leading to cell
death. Antimicrobial peptides may also have intracellular effects leading to cell death,
such as binding to DNA, inhibition of transcription, translation and protein synthesis,
inhibition of enzyme activity, inhibition of cell wall formation, alteration of cytoplasmic
membrane, or activation of autolysin or other non‐ membrane external targets [26].

There are three main proposed pore forming mechanisms—the carpet model, the
barrel‐ stave model, and the toroidal pore model. The carpet model entails the
accumulation of peptides on the cell membrane. Cationic peptides are electrostatically
attracted to the negative charges on the bacterial membrane and align parallel to the
membrane [40]. Hydrophobic interactions are also important in antimicrobial peptide
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binding [41]. When a certain threshold concentration is reached, it allows the peptide to
disrupt the membrane in a detergent‐ like fashion [42‐44].

Another pore‐ forming model is the barrel‐ stave model. In this model,
antimicrobial peptides insert into the membrane, forming a pore lined with the peptide
[45]. A similar mechanism is the toroidal‐ pore model. In this model, the membrane
bends continuously so that the polar head groups of the lipids are continuously in
contact with the α‐ helix of the antimicrobial peptide [46].

Some antimicrobial peptides have been shown to work together in a synergistic
manner [47, 48]. In the presence or absence of other antimicrobial peptides,
antimicrobial activity was impacted. In many cases, activity was increased more than
expected when used with another antimicrobial peptide. This may have implications in
the mechanism of different antimicrobial peptides as well as the conditions required for
optimal activity.

3.2

Defensins

There are two well‐ studied groups of antimicrobial peptides in mammals—the
defensins and the cathelicidins [49‐52]. Studies of these two groups of antimicrobial
peptides have led to increased understanding of the conditions necessary for
antimicrobial activity, characteristics of antimicrobial peptides, and possible
mechanisms of action.
10

There are two main classes of defensins in humans, α‐ and β‐ defensins. Both are
composed of β‐ sheets linked by disulfide bonds between the conserved cysteine
residues. The pattern of disulfide bridges determines whether a defensin is an
α‐ defensin or a β‐ defensin. There are six known α‐ defensins and four known
β‐ defensins [26]. α‐ defensins are primarily found in granules released by neutrophils
or by the Paneth cells of the small intestine [53] and are, on average, slightly shorter
than β‐ defensins. β‐ defensins are secreted in mucosal tissues, including in the eye, skin,
oral mucosa, and urogenital and respiratory systems [35]. There is also a circular form
of defensin, which is known as a θ‐ defensin, identified first in rhesus macaques and
found only in non‐ human primates [54, 55]. Defensins are highly soluble in water [35]
and are released upon tissue damage or injury [39]. The exact mechanism of defensin
killing is still unknown but it most likely involves oligomerization [56, 57] and
electrostatic attraction between the cationic peptide and the negatively charged bacterial
membrane [35], possibly utilizing the carpet model.

3.3

Cathelicidins

Cathelicidins are another well studied group of antimicrobial proteins that all
share a domain known as the cathelin domain. LL‐ 37, also known as hCAP18, or
FALL‐ 39, is the only known human cathelicidin. It is an amphipathic α‐ helix and is
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primarily expressed by neutrophils [58] and monocytes [59]. LL‐ 37 disrupts the
bacterial lipid bilayer via the toroidal pore model [60] .

3.4

Other antimicrobial peptides

Other peptides have also been shown to have antimicrobial activity in humans.
These include ribonucleases, phospholipase A2, histones, and platelet‐ derived factors.
Antimicrobial activity as a secondary or additional function is a common theme
amongst these. Peptides such as psoriasin or lysozyme also exhibit antimicrobial
activity [61‐65].

4.

Antimicrobial chemokines

Defensins have been shown to bind, activate, and induce migration via the
chemokine receptor CCR6, a receptor found on both immature dendritic cells and
memory T cells [59, 66‐68]. Although there is no clear sequence similarity between
chemokines and defensins, these molecules resemble each other in charge, size and
structure [69]. Although chemokines have been traditionally classified based on their
ability to induce cellular chemotaxis, various chemokines, including CCL28 and CCL25,
also show antimicrobial activity in vitro [70, 71].
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4.1

CCL28

CCL28, previously known as mucosae‐ associated epithelial chemokine (MEC),
was first identified and reported in 2000 by two independent groups [17, 72]. As
described by Pan et al., it acts as a ligand for two separate receptors: CCR3 and CCR10.
CCL28 also has 6 cysteine residues, whereas most chemokines contain 4 cysteines.

CCL28 is selectively expressed in mucosal tissues, such as the salivary and
lactating mammary glands, trachea, stomach, and large intestine [71, 72]. The
C‐ terminus of human CCL28 shows significant sequence homology to histatin‐ 5,
another well‐known antimicrobial peptide [71]. CCL28 attracts plasma cells,
particularly IgA antibody secreting cells (ASCs) via CCR10 [71‐74]. CCR3, the other
cognate receptor, is present on eosinophils and activated T lymphocytes [75].

CCL28 shares significant homology (about 40% at the protein level), with CCL27,
although CCL27 shows no antimicrobial activity [70]. CCL27, also known as cutaneous
T‐ cell attracting chemokine, or CTACK, is expressed in the skin by keratinocytes and is
another CCR10 ligand. As described above, CCL28 is expressed on mucosal surfaces
and can attract IgA plasma cells, memory lymphocytes and eosinophils [72]. CCL28 is
encoded on human chromosome 5, by at least 4 exons with large introns [72], while
CCL27 is on chromosome 9 [76]. CCL28 as a protein is 127 amino acids long [17] with a
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longer C‐ terminus than CCL27. This may contribute to their different properties, as the
C‐ terminal end of chemokines has been shown to have α‐ helical structure.

Further studies with CCL28 have shown that antimicrobial activity is dependent
on highly charged amino acids in the C‐ terminal region. Charge reversal and deletion
mutations in the C‐ terminus led to the identification of a sequence of positively
charged amino acids, conserved across species, that is necessary for microbe killing [77].
Studies have shown the C‐ terminus to be necessary for full antimicrobial activity but
not sufficient by itself for effective antimicrobial activity. Fusion proteins consisting of
the N‐ terminus of CCL27, which alone does not have any known antimicrobial
properties but is highly homologous to the N‐ terminus of CCL28, and the C‐ terminus
of CCL28 did show effective microbe killing. A fusion protein between the N‐ terminus
of CCL5 and the C‐ terminus of CCL28 did not show killing similar to the full length
CCL28, suggesting that some part of the N‐ terminus assists in bacterial killing [77].

Additional studies with CCL28 also show that osmotic pressure is important in
antimicrobial activity. At normal concentrations, CCL28 fails to kill bacteria in high salt
or sugar solutions [78]. Chemokines are still able to bind bacteria in such conditions but
their antimicrobial properties are restricted. Whether CCL28 binds to a specific protein
or receptor on the bacterial surface or if it binds through electrostatic and hydrophobic
interactions is still unknown.
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Binding of antimicrobial peptides—including antimicrobial chemokines—is the
first step in membrane permeabilization and antimicrobial action. However, peptide
binding does not always lead to cell death, as peptide binding may still occur without
accompanying cell lysis (unpublished observation).

4.2

CCL25

CCL25 is another antimicrobial chemokine used in this study. It is highly
expressed in the thymus and small intestine [79] and has also been shown to have
antimicrobial activity [70]. Its receptor, CCR9, is expressed on IgA ASCs as well as some
T cells [80‐82].

4.3

in vivo vs. in vitro effects

The physiologic relevance of antimicrobial chemokines in vivo is less understood
than their role in cell migration. Many antimicrobial chemokines have been shown to
exhibit antimicrobial activity only at high chemokine concentrations or low salt
concentrations. Similar to antimicrobial peptides, chemokines can also be upregulated
or induced. This may enable them to create microenvironments in which inhibitory salt
concentrations may become negligible [69].
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5.

Bacterial defense mechanisms

Despite the complex systems designed to maintain human health, diseases
caused by bacteria continue to be a problem. Continued evolution in both the human
immune system and bacterial defensive and offensive strategies make it so that, in the
words of the Red Queen of Lewis Carroll’s Wonderland, “it takes all the running you
can do, to keep in the same place” [83].

One of the main defenses of bacteria is their outer wall. In Gram‐ positive
bacteria, this consists of a thick layer of peptidoglycan, a chain of alternating
N‐ acetylglucosamine (GlcNAc) and N‐ acetylmuramic acid (MurNAc) residues, cross‐
linked together by short peptide chains. Peptidoglycan is important in maintaining the
structure of the cell wall and resisting osmotic pressure changes [84]. Gram‐ negative
bacteria have only a thin layer of peptidoglycan, sandwiched between two
phospholipid membranes. The inner membrane of Gram‐ negative bacteria is where
major cellular functions occur, including electron transport, DNA synthesis, and
nutrient transport. The outer membrane is polar, with the inner leaflet being similar to
the inner membrane while the outer leaflet is primarily composed of LPS.

5.1

LPS

LPS constitutes ~75% of the outer leaflet of the outer membrane of Gram‐
negative bacteria [85]. It is composed of three distinct parts: Lipid A, the oligosaccharide
16

core and the repeating O‐ units that make up O‐ antigen. Lipid A consists of a
β‐ 1, 6‐ linked, acylated glucosamine disaccharide. The fatty acids, which anchor lipid A
and LPS into the phospholipid membrane, can vary between species in number and
length [86]. Negatively charged phosphate groups on lipid A, at positions 1 and 4’,
provide anchors for divalent cations to bridge neighboring LPS molecules [87].
Phospholipid patches and porins make up the rest of the outer membrane outer leaflet.

Lipid A and the core oligosaccharides are generally conserved between species
and seem to be the minimum requirements for bacterial survival. The oligosaccharide
core can be divided into the inner and outer cores. The inner core is more tightly
conserved between species, and usually includes 3‐ deoxy‐ D‐ manno‐ oct‐ 2‐ ulosonic
acid (Kdo), L‐ glycero‐ β‐ D‐ manno‐ heptose (L, D‐ heptose or L, D‐ Hep) and other
sugar residues. At the least, Kdo residues attached to lipid A can suffice as LPS. Kdo is
characteristic and essential to LPS [88].

Major variation between species is usually within the O‐ antigen. O‐ antigen
variation includes differences in the number of O‐ units added, the types of sugars
incorporated, and the linkage between repeating units [86]. Regions internal to the outer
core and O‐ antigen are not involved in surface interactions and so are not as prone to
change [86]. O‐ antigen molecules also serve as bacteriophage receptors and may have
evolved to become more resistant to bacteriophages [89]. Additionally, the importance

17

of lipid A and the inner core in maintaining outer membrane stability may make it less
likely to change.

The immune response to LPS comprises TLR4 recognition, assisted by CD14 and
MD‐ 2, triggering the production of pro‐ inflammatory cytokines, including TNF‐ α and
IL‐ 1 [90, 91].

5.1.1

LPS modifications

Two component systems are commonly used by bacteria to rapidly adjust to
changing environments and conditions. Two component systems consist of a sensor
kinase and a response regulator. Upon sensing the presence or absence of certain ions or
nutrients, the sensor kinase phosphorylates the response regulator, leading to an
increase in transcription of certain genes.

Two such systems are particularly relevant to bacterial resistance to
antimicrobial peptides. In Salmonella enterica serovar Typhimirium and Pseudomonas
aeruginosa, the PhoP/PhoQ system responds to low calcium, low magnesium
concentration, or low pH, typical of the microenvironment in the phagosome of a
neutrophil. The presence of cationic antimicrobial peptides can also activate this system.
Activation increases acylation of lipid A, specifically by adding palmitoyl groups [92].
This decreases membrane fluidity, making it more rigid and thus harder for
antimicrobial peptides to penetrate [85]. PhoP/PhoQ activation also activates the
18

PmrA/PmrB two component system [93]. This system results in incorporation of
aminoarabinose (Ara4N) or addition of ethanolamine (EtN) to lipid A, masking the
negative charges of the phosphate groups [94‐96]. This modification of LPS makes the
overall charge of bacteria less negative, making it less attractive to antimicrobial
peptides and more resistant to polymyxin. Polymyxin is an antibiotic that is also
attracted to the negatively charged bacterial membrane and destabilizes the electrostatic
and hydrophobic interactions of the membrane [97]. In Yersinia, this polymyxin‐
resistance operon, pmrF, is actually independent of PmrA/PmrB, instead being directly
upregulated by PhoP/PhoQ [98].

5.1.2

LPS synthesis

LPS synthesis occurs in two general phases. Lipid A and the core
oligosaccharides are synthesized and assembled on the cytoplasmic side of the inner
membrane. The lipid A and core are translocated to the periplasm, where repeating
O‐ units, making up the O‐ antigen are added by waaL, the O‐ antigen ligase. The
number of O‐ units added, thus determining the length of the O‐ antigen, is determined
by the wzz gene product, the O‐ antigen chain length determinant. The whole molecule
is then transported to the outer membrane.

19

5.2

Other bacterial defenses

In addition to changing or masking surface charges, bacteria have developed a
number of defense mechanisms to either avoid or overcome the immune system. These
may include efflux pumps that rid the cell of antimicrobial peptides [99], steric
hindrance [100], preventing binding by decoy trapping [101] or capsule or biofilm
formation, secretion of proteases to directly degrade antimicrobial peptides [102], or
preventing the host from making antimicrobials in the first place [103].

6.

Yersinia psuedotuberculosis and the rfaD operon

Yersinia pseudotuberculosis is a Gram‐ negative bacterium that can cause a
tuberculosis‐ like disease in animals, including beavers, hares, horses, goats and
monkeys [104‐107]. Symptoms may include local necrosis and granulomatous
inflammation in the lymph nodes, spleen and liver. In humans, it usually causes a self‐
limiting, food‐ borne, gastroenteric disease that can mimic the pains of appendicitis [108,
109]. Y. pseudotuberculosis, similar to Salmonella or Shigella, travels to the lymph nodes by
passing through the M cells of the small intestine. It is closely related to Yersinia pestis,
which evolved from Y. pseudotuberculosis relatively recently (1500‐ 20000 years ago)
[110]. Y. pestis is more virulent and causes more disease pathology than
Y. pseudotuberculosis, including bubonic plague, or the Black Death, and pneumonic
plague, a highly contagious, airborne disease with a fatality rate approaching 100%
20

[111]. A third species of the genus Yersinia, Yersinia enterocolitica, is also pathogenic to
humans, but less so, causing a gastroenteric disease like Y. pseudotuberculosis. Y. pestis
and Y. pseudotuberculosis have been shown to be more resistant to the activity of cationic
antimicrobial peptides than Y. enterocolitica [112].

6.1

Yersinia LPS

Y. pseudotuberculosis lipid A acylation changes with temperature. At 21°C,
Y. pseudotuberculosis produces tetra‐, penta‐, and hexa‐ acylated lipid A. At 37°C, it
produces two major forms: a tetra‐ acylated form similar to Y. pestis and a penta‐
acylated form, which results from addition of a palmitoyl group (C16:0) [113]. Studies
with a PhoP knockout in Y. pestis showed that this temperature dependent shift in
acylation was, interestingly, PhoP independent. Ara4N addition still occurred in a
PhoP‐ dependent manner. [113]

LPS consisting only of lipid A and Kdo are known as deep‐ rough mutants.
Rough mutants include both lipid A and elements of the core oligosaccharide and have
increased hydrophobicity. Bacteria with full length O‐ antigen LPS are considered to
have smooth LPS.

Natural isolates of Y. pestis are rough, although they still carry a mutated
O‐ antigen gene cluster [114, 115]. Y. pseudotuberculosis O‐ antigen expression is
significantly reduced at 37°C [116, 117].
21

6.1.1

Yersinia inner core

Lipid A and the core oligosaccharide structures are generally conserved between
members of the same genus. The chemical composition for the core regions of Y. pestis,
Y. pseudotuberculosis and Y. enterocolitica were found to be the same [118], although the
actual structures differ slightly. The core structure for Y. pestis LPS (KM218 grown at
25°C) was described in 2002, as determined by NMR spectroscopy and electrospray‐
ionization mass spectroscopy (ESI‐MS) [119]. Y. enterocolitica and Y. pestis share similar
but not identical cores [118]. The main core backbone, consisting of L, D‐ Hep III  L,D‐
Hep II  L, D‐Hep I  Kdo, is conserved between Y. pestis and the three serotypes of
Y. enterocolitica studied (O:3, O:8 and O:9) [118]. ESI‐MS was also used to compare the
LPS of Y. pestis and Y. pseudotuberculosis and data suggest that their core structures are
virtually identical, excepting differences that occur as a result of temperature‐
dependent variations [120]. These studies used Y. pseudotuberculosis serotypes O:3 and
O:4. The Y. pseudotuberculosis core is similar in all serotypes [121]. Additionally, studies
using a Y. pestis specific bacteriophage found that the phage receptor, Y. pestis LPS core,
was also present in Y. pseudotuberculosis [122]. This shared core structure includes at the
least two Kdo residues (or Kdo and Ko) and three L, D‐heptose residues [123]. While
the core structure for the Y. pseudotuberculosis strain used in this study (O:1b) has not
been described, from the data described above, we expect that the core structure is as
shown in Figure 1. Figure 1 shows the Y. pestis core when grown at 25°C with potential
22

substitutions between D, D‐ heptose and galactose as well as between Kdo and Ko
(adapted from [119]).

Growth at different temperatures affects what other sugars, including glucose,
galactose, D, D‐ heptose and D‐ glycero‐ D‐talo‐oct‐2‐ulosonic acid (Ko), are incorporated
in the inner core. Both Y. pestis and Y. pseudotuberculosis have temperature‐ dependent
structure variations [120]. At 37°C, the core consists of D, D‐ Hep, L, D‐ Hep III, L, D‐
Hep II, L, D‐ Hep I, and a Kdo disaccharide with glucose branching from L, D‐ Hep I.
At 6°C, D, D‐ heptose is replaced with β‐D‐glucose and one Kdo residue is replaced Ko.
At 25°C, a mix of glycoforms containing D, D‐ Hep + Ko and Gal + Kdo are found [123].
Incorporation of galactose instead of D, D‐ heptose is under PhoP/PhoQ control [41,
123]. The biological role of these different glycoforms or substitutions is not exactly
known [41, 120].

6.2

rfaD operon

rfaD, alternatively known as gmhD, hldD or htrM, encodes ADP‐ L‐ glycero‐ D‐
manno‐ heptose‐ 6‐ epimerase. This gene is responsible for the epimerization of L, D‐
heptose from D, D‐ heptose. L, D‐ heptose is the preferred isomeric form of heptose
used for at least the first two heptose residues in the LPS inner core. While D, D‐
heptose can be used, studies have shown it has less activity and that the physiological
donor is indeed L, D‐ heptose [85].
23

In Yersinia, rfaD is part of a three gene operon, also including, in order, rfaF and
rfaC (alternatively known as waaF and waaC, respectively). Both are
heptosyltransferases, with rfaC responsible for transferring the first L, D‐ heptose
residue onto the Kdo and rfaF encoding the transferase adding on the second L, D‐
heptose residue.

A fourth gene, rfaL (or waaL), encoding the O‐ antigen ligase, is found in the
homologous operon in E. coli. However, in E. coli the core biosynthesis genes are found
right next to the O‐ antigen biosynthesis genes (waaQ operon) and the Kdo transferases.
While the Kdo transferase does neighbor the rfaD operon, the O‐ antigen biosynthesis
genes are found elsewhere in the Yersinia genome.

7.

Experimental Approach

Using Y. pseudotuberculosis (IP 32953, serotype O:1b) and CCL28 as models, we
sought to find genes that are important in bacterial resistance to antimicrobial peptides,
specifically antimicrobial chemokines. To achieve this, we performed random
transposon mutagenesis, screening for mutants with altered outer membrane
composition and/or increased chemokine binding. Sequencing of the first high binding
mutant identified, called mutant 27, revealed an insertion in the rfaD gene.

To further explore the role of rfaD in chemokine binding and chemokine‐
mediated killing, we transcomplemented the mutant and measured its effects. Because
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these three genes are transcribed and translated as an operon, it was not clear if the
mutation in rfaD was solely responsible for the observed high‐ binding phenotype or if
the other two genes were somehow involved. Accordingly, the partial operon,
including rfaD and rfaF (rfaDF), was also transcomplemented as was the whole operon
(rfaDFC). Complemented strains were then compared to wild type bacteria and to
mutant 27 bacteria in terms of chemokine binding and killing by CCL28 or polymyxin.
qPCR was used to analyze gene expression differences in the mutant and
complemented strains.

Additionally, we sought to physically characterize mutant 27 bacteria compared
to wild type bacteria and complemented strains in terms of size, growth patterns, and
LPS expression.

We hypothesize that rfaD and possibly rfaF or rfaC play a key role in preventing
antimicrobial peptide binding and possibly chemokine‐ mediated killing. A defect in
LPS synthesis may lead to greater accessibility to the cell wall, thus granting increased
access to the bacterial membrane for antimicrobial chemokines. Through mutating
different genes involved in LPS synthesis and measuring the differences in chemokine
binding and killing ability, we may be able to find genes important in bacterial
resistance to antimicrobial chemokines.
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MATERIALS AND METHODS

Bacterial strains and growth conditions

Y. pseudotuberculosis IP 32953, a fully virulent clinical isolate from a patient [124],
was used as the wild type and transposon mutagenesis and subsequent
complementation was performed in it. Unless otherwise mentioned, all Yersinia species
were grown at room temperature in tryptic soy broth (TSB) with shaking or on tryptic
soy agar (TSA). Yersinia cultures for RNA extraction were grown at 30°C on brain‐ heart
infusion (BHI) plates. Ampicillin (100 μg/mL) or kanamycin (30 μg/mL) was added
when necessary. E. coli SM10 carrying pRL27 [125] was used as the transposon donor in
mutagenesis and E. coli DH5α was used as a cloning host. E coli strains were grown at
37°C.

Transposon mutagenesis

Random transposon mutagenesis in Y. pseudotuberculosis was performed by
biparental mating with E. coli SM10 harboring pRL27, which contains a Tn5 element
encoding kanamycin resistance [125]. Kanamycin resistant insertion mutants were
selected and pre‐ screened in one of two ways: (1) on Congo red agar to test for altered
outer membrane composition, or (2) by magnetic separation, to select mutants with
increased chemokine binding. Mutants were then cycle sequenced to find the precise
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location of the transposon insertion. All sequencing was done at the DNA Sequencing
Center at Brigham Young University.

Flow cytometry binding assays

To assure logarithmic growth phase, 10 μL of overnight culture were inoculated
into 3 mL TSB plus the appropriate antibiotic and grown for 3 hours. Bacteria were
diluted 1:20 in filtered phosphate buffered saline (PBS) supplemented with 0.5 g bovine
serum albumin (BSA) and 0.2 nM chemokine was added and incubated on ice for
30 minutes. Biotin‐ conjugated anti‐ chemokine antibody was added and incubated for
30 minutes. Finally, fluorescent streptavidin‐ conjugates were added, incubated for at
least 30 minutes, washed and then fluorescence was measured using the
BD FACSCanto II flow cytometer and analyzed using FACSDiva software
(BD Biosciences, San Jose, California). Samples were washed between each step and all
incubations were done on ice.

Complementation

Primers were designed to amplify rfaD, rfaF, and rfaC (see Table 1). A region of
310 base pairs upstream of rfaD was included so that the native promoter would also be
cloned in complementation plasmids. PCR products were cloned using the Fermentas
CloneJET cloning kit (Glen Burnie, Maryland) and transformed into DH5α competent
cells (New England BioLabs, Ipswich, Massachusetts). Plasmids were isolated from
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ampicillin resistant clones using the QIAprep Spin Miniprep Kit (QIAGEN, Valencia,
California) and then cycle sequenced to confirm amplification of the proper gene. Once
this was confirmed, complementation plasmids were transformed into mutant 27 via
electroporation. Transformations were verified with colony PCR using Taq polymerase.

PCR cycling conditions were as follows: 98°C for 30 seconds, 30 cycles of 98°C for
10 seconds and 72°C for 60 seconds, then 72°C for 5 minutes. For colony PCR, a 5
minute denaturation step was included at the beginning followed by 30 cycles of 94°C
for 30 seconds, 63°C for 30 seconds, 72°C for 90 seconds with a 5 minute extension step
(at 72°C) at the end.

Killing assays

Bacteria were grown to mid‐ logarithmic phase (OD600 between 0.5‐ 0.6) and
diluted 1:25 in filtered potassium phosphate buffer (PPB). After addition of chemokine
(0.4 nM CCL28), polymyxin (initial concentration= 10 μg/μL) or BSA (0.01%), bacteria
were incubated at room temperature until the appropriate time point. 20 μL of bacteria
were removed at each time point and put on ice in PBS plus counting beads (diluted
1:62500, Polybead ® Polystyrene 1 μm Microspheres, Polysciences Inc., Warrington,
Pennsylvania). Propidium iodide (PI) (Invitrogen, Carlsbad, California) was added just
before reading on the flow cytometer. Viable bacteria were determined by subtracting
PI positive bacteria from the total number of bacteria counted per 30000 beads. Percent
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survival was calculated by dividing viable bacteria of the sample by viable bacteria in
the BSA control.

Killing assay set up was the same for CCL28 and polymyxin but the
concentrations and time points used were different. CCL28 assays were done over 5
hours with a consistent concentration. Polymyxin assays were performed with differing
polymyxin concentrations at time points 0 hours and 2 hours.

Growth curves

Growth curves were performed using the same protocol as the killing assays
except the initial subculture was diluted 1:1000 in TSB and there was no addition of
chemokine or BSA. Results were plotted as fold‐ increase (compared to the number of
cells at time zero) over time.

qPCR cDNA preparation and cycling conditions

RNA extraction from overnight cultures was done using the Direct‐ zol RNA
MiniPrep Kit (Zymo Research, Irvine, California) following the protocol for cell
suspensions as instructed by the manufacturer. DNAse treatment was done using the
Ambion TURBO DNA‐ free Kit (Invitrogen, Carlsbad, California). cDNA synthesis was
done using the SuperScript VILO cDNA Synthesis Kit or SuperScript VILO MasterMix,
both from Invitrogen (Carlsbad, California).
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qPCR primers were designed using the PrimerQuest tool at Integrated DNA
Technologies (idtdna.com) and are listed in Table 2. Primers were ordered from
Invitrogen (Carlsbad, California) and the Maxima SYBR Green/ROX qPCR Master Mix
(2x) from Fermentas Molecular Biology Tools (Glen Burnie, Maryland) was used. 3 μM
each forward and reverse primers (1.5 μM for dnaE primers) were added to the master
mix and DNA. The comparative CT method was used, with dnaE as the endogenous
control. ROX, included in the master mix, was used as the passive reference dye.

qPCR cycling conditions were as follows: 10 minute initial denaturation at 95°C
followed by 40 cycles of 95°C for 15 seconds then 60°C for 1 minute for annealing and
extension. The melt curve analysis at the end included 95°C for 15 seconds, 60°C for 1
minute followed by the temperature increasing in increments of 0.3°C. The reaction was
performed on a StepOne Real‐ Time PCR System and analyzed using StepOne Software
v2.1 (Applied Biosystems, Carlsbad, California).

Reactions were done in duplicate and results are the average of 5 independent
experiments (or 2 experiments for DFC (forward)). Results are representative of 3
independent RNA extractions.

LPS isolation and analysis

1 mL of overnight culture (OD600 between 1‐ 2) was pelleted and resuspended in
100 μL Tris/Tricine sample buffer. After boiling for 10 minutes, proteinase K was added
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and samples were allowed to incubate for 1 hour at 60°C. After another 10 minute
boiling step, samples were separated by sodium dodecyl sulfate‐ polyacrylamide gel
electrophoresis (SDS‐ PAGE; 10‐ 20%). LPS staining was done using the Pro‐ Q Emerald
300 LPS Gel Stain Kit (Invitrogen, Carlsbad, California) with the manufacturer’s
directions followed exactly. Briefly, this included overnight fixation in 50%
methanol/5% acetic acid at room temperature followed by two 20 minute washes with
3% glacial acetic acid. Oxidation for 30 minutes with periodic acid was followed by
three additional washes. The gel was stained with a freshly prepared staining solution,
as directed by the manufacturer, for 2 hours at room temperature, washed twice more
and then visualized on a UV transilluminator.

Scanning electron microscopy sample preparation

Scanning electron microscopy (SEM) was used to measure wild type and mutant
27 bacteria. A vacuum filter system was used to mount bacterial samples (sub‐ cultured
to represent mid‐ logarithmic phase growth) suspended in filtered PPB on a
membranous filter. Polycarbonate track etch filters with a pore size of 0.4 μm were
purchased from Whatman (GE Healthcare, Kent, United Kingdom). Samples were fixed
in 1% buffered glutaraldehyde for at least 1 hour. Filters were then washed in PPB four
times, 10 minutes each. The filters were then left in a secondary fixative (osmium
tetraoxide, OsO4) for at least 2 hours. Distilled water was then used to wash the OsO4
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out of the sample (six washes, 10 minutes each). Following the distilled water washes,
samples went through an ethanol dehydration series (10%, 30%, 50%, 70%, 95%, and
100%). Filters were washed three times in 100% ethanol and then once in 100% acetone.
Critical point drying was performed with at least four wash/purge cycles (with liquid
CO2), followed by mounting on clean 1” stubs and sputter coating with gold. Samples
were viewed in the environmental scanning electron microscope (ESEM) in hi‐ vacuum
mode. Accelerating potential, spot size, magnification and working distance were all
optimized. All samples were measured at a magnification between 1500X‐ 38000X and
only cells laying flat were measured. ImageJ image processing and analysis software
was used for all measurements (http://rsbweb.nih.gov/ij/).
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RESULTS

Binding assays

Yersinia pseudotuberculosis mutants were initially screened based on their ability
to bind chemokine better than wild type bacteria. Antimicrobial chemokine binding is
regarded to be the first step toward cell death. Mutant 27 consistently showed better
binding of both CCL28 and CCL25 than the wild type, over 50‐ fold and 100‐ fold,
respectively. Somewhat surprisingly, addition of the rfaD complementation plasmid
failed to restore the wild type phenotype. Complementation with rfaDF appeared to
partially restore wild type binding while the full length operon completely restored
wild type binding (Figure 2A). CCL28 binding was not statistically different between
mutant 27, rfaD+ and rfaDF+ strains (p> 0.01). There was also no statistical difference
between wild type and rfaDFC+ binding (p= 0.09). rfaF and rfaC, in individual
transcomplementation assays showed no effect on chemokine binding (data not shown).

CCL25 binding patterns mirrored CCL28 binding (Figure 2B), suggesting that the
two chemokines may bind in similar fashions. Mutant 27 binding was not statistically
different from rfaD+ or rfaDF+ binding (p> 0.01) but the rest of the samples were
statistically different from each other. These results suggest that a fully functional L, D‐
heptose epimerase along with appropriately spaced heptosyltransferases is important
for bacteria in avoiding binding by antimicrobial chemokines.
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Killing assays

In order to see if, and how closely, chemokine‐ mediated killing mirrors
chemokine binding patterns, killing assays using CCL28 were performed on wild type,
mutant 27, rfaD+, rfaDF+, and rfaDFC+ bacteria. A similar pattern of complementation
was seen as in the chemokine binding assays. Figure 3A, which presents bacterial
survival data, shows that the complete operon fully restores wild type resistance to
CCL28 at all time points (p> 0.01) whereas rfaD+ and rfaDF+ show no difference from
mutant 27 susceptibility compared to the wild type (also at all time points, p> 0.01).

In our assay, chemokine‐ mediated killing and bacterial survival are functions of
the total number of cells counted and the number of PI positive cells. Thus, we also
looked at both of these parameters individually for additional insight. Experiments in
which BSA was used as a negative control (in place of CCL28) (Figure 3B) showed no
significant difference between the number of cells counted in any sample at all time
points (p> 0.01). In the CCL28 treated bacteria (Figure 3C), at all time points, mutant 27
and rfaD+ results were significantly different from the wild type cell count (p< 0.01). At
time points 3 hours and 5 hours, rfaDF+ was also significantly different from the wild
type. At all time points, there was no difference between the number of cells counted in
the mutant 27 sample compared to rfaD+ bacteria (p> 0.01). Sheer number of surviving
bacterial cells increased with the number of genes complemented.
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The number of PI positive cells in both the BSA treated (Figure 3D) and CCL28
treated samples (Figure 3E) are in the hundreds (out of thousands of cells counted per
30000 beads counted). At time points 3 hours and 5 hours, rfaD+ and rfaDFC+ were
found to have significantly different numbers of PI positive cells compared to the wild
type, while the mutant and rfaDF+ bacteria were not different (using p= 0.01 for
significance).

We next designed experiments to determine if resistance to a different
antimicrobial peptide would be similarly affected by the rfaD mutation and subsequent
complementations. In these experiments, the well characterized antimicrobial peptide
polymyxin was used. Although the assays were performed following the same protocol
as described above for the CCL28 assays, instead of analyzing survival at different time
points, different dilutions of polymyxin were used. Time points 0 hours and 2 hours
were used in all experiments.

Killing assays with polymyxin, which disrupts the bacterial membrane, were
performed on wild type, mutant 27, and all three complemented strains. As seen in
Figures 4A and 4B (time points 0 hours and 2 hours, respectively), mutant 27 was
extremely sensitive to polymyxin and much more susceptible than all of the other
strains tested. For example, at a concentration where more than 85% of the wild type
survives after 2 hours (1:500 dilution), mutant 27 showed less than 1% survival.
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Transcomplemented strains, while being less susceptible to polymyxin activity, still
show only between 35‐ 50% survival. At the concentration where mutant 27 survival
exceeds 50% (between 1:4000 and 1:8000 dilutions), the survival rate for the
complemented strains are close to the wild type. At time point 2 hours, mutant 27
showed significantly lower survival compared to the wild type through the 1:4000
polymyxin dilution. rfaD+ differs from the wild type through the 1:2000 dilution while
rfaDF+ differs at the only the first two dilutions (1:500 and 1:1000 dilutions). Mutant 27
is also different from the three complemented strains through the 1:4000 dilution
(p< 0.01), as seen in Figure 4B.

We also looked at cells counted and PI positive cells for the polymyxin assays.
Figure 4D shows that, at time point 2 hours, mutant 27 showed, at all concentrations of
polymyxin except 1:16000, significantly fewer cells counted compared to the wild type.
rfaD+ and rfaDF+ were also different from the wild type at higher concentrations of
polymyxin (1:500 and 1:1000 dilutions) (p< 0.01).

Mutant 27 showed significantly more PI positive cells than the wild type,
through the 1:8000 dilution, or any of the complemented strains, through the 1:4000
dilution (p< 0.01). All strains, at the highest concentration of polymyxin, show upwards
of 500 PI positive cells (Figure 4F), more than the general number of PI positive cells in
the CCL28 treated samples.
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In these assays, the term “percent viability” integrates the number of PI negative
cells and the number of total cells present (as determined by using counting beads as an
internal reference). In short, this number reflects bacteria that have had their
membranes permeabilized (PI positive) as well as cells that have lysed or failed to
divide (total cells counted) and is an overall measure of the antimicrobial activity of the
chemokine or antimicrobial peptide. These data suggest some interesting characteristics
which may hint at possible differences in mechanism between CCL28 and polymyxin.
With CCL28, inhibition of growth or cell lysis occurs (manifest as fewer numbers of
cells counted). For polymyxin, membrane permeability seems to be more important.
This is seen by the increase in PI uptake in polymyxin treated cells. Ultimately, both
antimicrobial peptides result in fewer bacterial cells in a solution. However, these data
suggest that CCL28 may act by inhibiting cell proliferation whereas polymyxin may act
by permeabilizing the bacterial cell membrane.

qPCR gene expression analysis

Sequencing of the transposon insertion site of mutant 27 showed that the rfaD
gene was interrupted; however, an rfaD complemented strain failed to restore the wild
type phenotype for binding or killing. Because rfaD is part of a three gene operon, it was
not clear if the mutation in rfaD was solely responsible for the observed high‐ binding
phenotype or if the other two genes were also involved. Binding and killing data,
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described above, suggested that each of the other genes in the operon play an important
role. This would seem to indicate that the insertion mutation was a polar mutation,
disrupting the downstream reading frames. To address this issue, we next used qPCR
to assess gene expression in all complemented strains. Results are shown in Figure 5.
Interestingly, the rfaD+ strain showed about equal expression of all three genes, despite
not restoring the wild type phenotype.

There are two separate rfaDFC+ clones. When first cloning the full operon, we
had clones where the operon was in “reverse,” (“Rev”) being expressed only under the
control of its endogenous promoter. A later clone (“Fwd”) had the full operon under
control of its endogenous promoter as well as the promoter on the cloning plasmid.
These two clones showed drastically different expression patterns. The Fwd clone
showed high levels of expression for all three genes, with the highest expression for
rfaD. The Rev clone also showed high rfaD expression but minimal or no expression of
rfaF and rfaC. Both clones restore wild type binding and killing phenotypes.

There are a few possible reasons rfaD+ showed high expression but failed to
complement the phenotypes. These possibilities include some sort of protein‐ protein
interaction which may be needed, but because the genes were expressed from a plasmid
compared to the chromosome, they might not have been in the correct spatial
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orientation to interact appropriately. Also, because the cloning vector was a multicopy
plasmid, this could abnormally affect the level of expression of plasmid encoded genes.

Growth curve analysis

In order to investigate if the rfaD mutation affected bacterial growth as well as
bacterial death and susceptibility to antimicrobial chemokines, a growth curve was
performed. Growth was measured as fold increase over the number of bacteria in the
culture at time point 0 hours. Growth curve analysis over 5 hours (Figure 6) showed no
significant difference between the wild type, the mutant, and the rfaD+, rfaDF+, or
rfaDFC+ complemented strains. At time point 5 hours, mutant 27 did show slightly
lower growth but it is not significantly different from the wild type.

Morphological characterization

Colony morphology

Consistent with similar growth patterns, there were also no obvious physical
differences between the wild type, mutant 27, or any of the complemented strains in
colonies plated on TSA plates (Figure 7). However, mutant 27 did precipitate out of
solution faster than the wild type or any of the complemented strains (data not shown).
While the rfaD+ strain was similar to the mutant 27 phenotype in other characteristics
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measured, including binding and killing, the mutation did seem to affect the
precipitation rate.

SEM analysis

Another aspect of physical characterization of the mutant is the size of individual
bacterial cells. Initial flow cytometry experiments suggested that mutant 27 was bigger
than the wild type, based on forward light scatter. However, SEM showed no obvious
differences between wild type and mutant 27 bacteria in size. Measurement of
hundreds of bacteria (WT, n= 228; mutant 27, n= 301) showed that mutant 27 is
significantly bigger (p= 0.0035) but, as shown in Figure 8, the size difference does not
seem to be relevant functionally (difference between the means= 0.148 μm). Mutant 27
did tend to be less uniform in size and may be tend to be slightly bigger, but the data
was not statistically significant (data not shown). SEM also did not show any obvious
differences in membrane surface characteristics between wild type bacteria (Figure 9A)
and mutant 27 bacteria (Figure 9B).

LPS analysis

Lastly, LPS expression in the mutant bacteria was examined to assess how a
mutated rfaD affects LPS composition. The predicted core structure for Mutant 27 is
shown in Figure 10. SDS‐PAGE followed by LPS specific staining (Figure 11) showed
that rfaDFC fully and completely complemented the mutant and restored wild type LPS
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expression and composition. It appears that some O‐ antigen is added with the
successive restoration of each gene in the operon as the amount of “normal” lipid A
plus core grows (lane 2‐ rfaD+; lane 3‐ rfaDF+). A faster migrating band, possibly
representing lipid A alone, decreased in amount as the lipid A plus core band grows.
Y. pseudotuberculosis grown at 37°C (lane 6) and Y. pestis (lane 7) were included as
controls because previous research has shown that neither of these strains express
O‐ antigen [115, 126, 127].

Interestingly, the core size of Y. pseudotuberculosis and Y. pestis differed, despite
expectations that their compositions are identical (see Figure 1 which shows the Y. pestis
core). This may be because they were grown at room temperature, at which multiple
glycoforms are usually present [123]. However, even the core structure of the wild type
Y. pseudotuberculosis still appears larger than the Y. pestis core. This could be due to
differences in sugar substitutions, resulting from slightly different growth conditions.
Alternatively, the rough version of Y. pseudotuberculosis may still have some part of the
first O‐unit attached, whereas Y. pestis has only the core sugars. Different serotypes
(Y. pseudotuberculosis) and different strains (Y. pestis) also may have slight differences in
their cores. While the basic frame is conserved (two Kdo residues and three heptoses),
other sugars may or may not be included.
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DISCUSSION

Using Y. pseudotuberculosis IP 32953 and CCL28 as models, we sought to find
genes that are important in bacterial resistance to antimicrobial peptides, specifically
antimicrobial chemokines. Following random transposon mutagenesis, mutants were
screened for their antimicrobial chemokine binding abilities and their susceptibility to
antimicrobial chemokine‐mediated killing. Many of the genes found in our screen to
increase antimicrobial chemokine binding were involved in O‐ antigen biosynthesis,
core biosynthesis, LPS regulation or in the pmr operon, which is responsible for the
incorporation of Ara4N to lipid A, aiding in resistance to cationic antimicrobial peptides
(see Table 3 for other mutants identified).

Specifically, we have shown that bacteria with a mutation in rfaD, whose gene
product is responsible for the epimerization of D, D‐ heptose to L, D‐ heptose, binds
CCL28 much more efficiently than the wild type. Additionally, this mutant is more
susceptible to CCL28‐ mediated killing as well as polymyxin killing. We have also
characterized the rfaD mutant strain, mutant 27, based on size, growth patterns, and
LPS expression.

To confirm that rfaD was responsible for the observed mutant phenotypes, we
transcomplemented the mutant with rfaD alone, rfaDF and rfaDFC. rfaD alone is not
sufficient to restore the wild type binding and killing phenotypes. It appears that the
42

whole operon needs to be present and transcribed from the same piece of DNA for
complete complementation to occur. Because rfaD is responsible for the last step of
heptose biosynthesis, the known roles of rfaF and rfaC as heptosyltransferases make
sense in this context. Heptose may need to be readily available or physically on hand
for the transferases to function appropriately and build the “normal” core. As seen on
LPS gels, the more “normal” core present, the more O‐ antigen can be added.

These results demonstrate that the rfaD operon is important in bacterial
resistance to a model antimicrobial chemokine, CCL28, and a prototypical membrane‐
binding antibiotic, polymyxin. Increased chemokine binding seems to be correlated
with increased susceptibility, although antimicrobial peptide binding may not always
be related to cell death.

Inactivation of the rfaD gene prevents full length O‐antigen from being added to
the LPS of Y. pseudotuberculosis. Absence of smooth LPS may relieve steric hindrance
that, in turn, may be preventing cationic antimicrobial peptides and chemokines from
reaching their primary target‐ the bacterial outer membrane. Mutant 27 binds
antimicrobial chemokine better and, presumably, this binding is at the surface of the
outer membrane. As this is assumed to be the first step in antimicrobial chemokine‐
mediated killing, it is also likely that the lack of full length O‐antigen contributes to the
increased susceptibility of mutant 27 to killing. Other antimicrobial peptides that bind

43

to the surface of the outer membrane and then form pores would also have increased
access to the surface and thus increased antimicrobial activity. While this model is
consistent with our data, it is also possible that other outer membrane proteins are
involved in chemokine binding and/or killing. Lack of full‐length O‐antigen may affect
the conformation and activity of these proteins [128]. If there is a specific binding site
for CCL28, it is still unknown.

Mutant 27 is not different in size or growth pattern from the wild type, as
determined by SEM, growth curves, and observation of colony growth on TSA plates.
We used SEM to visualize any differences in appearance between wild type bacteria
and mutant 27 bacteria. There were no visible differences. In the future,
immunoelectron microscopy may be used to visualize chemokine binding and any
resulting membrane effects. Experiments with different antimicrobial chemokines may
show differences in binding patterns (i.e. generalized or localized on the membrane
surfaces). Other mutants may likewise show different binding patterns with various
antimicrobial chemokines. Additionally, TEM may be used to study intracellular
chemokine targets and localization.
Many questions still remain about the nature of antimicrobial chemokines and
their in vivo activity. Killing assays with other antimicrobial chemokines, like CCL25,
can help generalize patterns of chemokine‐ mediated killing and determine if
antimicrobial chemokines as a class act in similar manners. Binding and killing assays
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done using the concentrations and conditions that would be found in in vivo
microenvironments can help elucidate the role of antimicrobial chemokines in vivo.
Some of these microenvironments may contain other antimicrobial peptides which may
work in synergy with antimicrobial chemokines. In this case, the lethal dose for each
may be reduced in the presence of the other. Likewise, multiple antimicrobials may be
able to overcome inhibitory salt or osmotic effects. However, they may also work
antagonistically. Preliminary results in our lab show that CCL28 actually protects
bacteria from the activity of penicillin. Penicillin acts on the cell wall of bacteria by
preventing cross‐ linking between molecules of peptidoglycan. Further studies are
needed to determine how CCL28 and other antimicrobial chemokines may interact with
other antimicrobials or antibiotics in vivo.

We have identified a gene that, when mutated, makes bacteria more susceptible
to the natural antimicrobial compounds of the human innate immune system.
Following this same experimental approach, we can find other genes important in
chemokine recognition and binding.

Genes that do affect antimicrobial binding and subsequent killing may be used as
targets for antibiotics in the future. Antibiotic resistant bacteria are an increasing
concern in the medical industry. Overuse or misuse of antibiotics has led to selection of
resistant bacteria that are no longer responsive to traditional antibiotics, including
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penicillin and other β‐lactams. The time and cost required to develop a new drug is ever
increasing. Additionally, continual misuse of antibiotics may make these novel drugs
obsolete much sooner than anticipated or desired. Drug design is also increasingly
difficult as the number of new targets unique to bacteria shrinks. Changing the way
drugs are designed may provide a new avenue for drug research and development.
Current drug therapy focuses on inhibiting bacterial cell growth or some other aspect of
bacterial survival. This research suggests that instead of trying to create drugs to kill
bacteria, it may be possible to enhance the efficiency of our immune defenses. This
could be done by targeting bacterial proteins that are important for resistance to
antimicrobial peptides and/or chemokines. Drugs targeting proteins such as those
involved in LPS biosynthesis would make it easier to eliminate bacteria that normally
would not be susceptible to antimicrobial peptide killing. Proteins involved in LPS
biosynthesis are ideal drug targets because there are no counterpart proteins in humans.
Moreover, most of them are highly conserved between many species of bacteria. Efforts
are already being made to create chemical inhibitors of key enzymes involved in LPS
biosynthesis [88]. Our screen and accompanying assays may provide additional
appropriate targets for such drug design.
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TABLES AND FIGURES

rfaD (F)

ACG AGT CG TGT CGA GTT GTT GTT C

rfaD (R)

CAT GGC CTA ACG GC ATT GGA ATT G

rfaF (F)

AAG AAT ATC TGG CCT GGC TCA ATC GC

rfaF (R)

CGT CAG CGC GGG TAA GGT ATG TAA A

rfaC (F)

TAC CGG CTA TCA CAA AGT CCG CAA

rfaC (R)

AGC ACC ACA TTG AGC CGT GGT TAT

Table 1. Primers used for construction of complementation plasmids. All primers are
written 5’‐ 3’.

rfaD (F)

TGT GCG TGA AAT TCT GCC ACA AGC

rfaD (R)

ATG GCC TTC ACG TGG ACC ATA AAC

rfaF (F)

GCC CAA CTC ATT TAA ATC CGC GCT

rfaF (R)

AGG AAA TAA CGC ATT TCG CCA CGC

rfaC (F)

AGC GGA ACA TTT CCC ACA CGT AGA

rfaC (R)

AAC AGC GTA ATG TTT GGG CGA TCC

Table 2. qPCR primers (5’‐ 3’).
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Hits

Name

Function

% positive
CCL25
binding
4.0

Mean
fluorescence of
positive cells
111

N/A

Wild type

2

pmrK

dolichyl‐ phosphate‐ mannose‐ protein mannosyltransferase

78.8

714

16

fcl *

GDP‐ fucose synthetase

69.8

761

69

816

1

Xanthine/uracil permease family protein

7

gmd*

GDP‐ D‐ mannose dehydratase

67.2

1068

3

ddhD*

CDP‐ 6‐ deoxy‐ delta‐ 3,4‐ glucoseen reductase

44.7

1118

2

rfaD

ADP‐ L‐ glycero‐ D‐ manno‐ heptose‐ 6‐ epimerase

44

1673

5

wbyK*

putative mannosyltransferase

40.2

723

1

pmrI

probable formyl transferase

35.6

1798

16

wbyL*

probable glycosyltransferase

35.4

504

3

rfaH

transcriptional regulation of capsule/LPS

26

287

22

manC*

mannose‐ 1‐ phosphate guanylyltransferase

20.5

385

Table 3. Selected Y. pseudotuberculosis Tn5 mutants with increased binding affinity to
CCL25. Many insertions occurred in lipopolysaccharide synthesis genes. Hits refer to
the number of individual Tn5 mutants found in the specific gene. * denotes genes
within the O‐ polysaccharide cluster.
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Figure 1. The inner core structure of Y. pestis grown at 25°C (adapted from [119]). Under
different growth condition, different glycoforms of the core sugars can be found (see
text for details) ([120, 123]). Kdo= 3‐ deoxy‐ D‐ manno‐ oct‐ 2‐ ulosonic acid.
Ko= D‐ glycero‐ D‐talo‐oct‐2‐ulosonic acid. L, D‐ /D, D‐ Hep= ADP‐L/D‐glycero‐β‐D‐
manno‐heptose. Glu= β‐D‐ glucose. Gal= galactose
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A.

*

*

*

B.

+
+

Figure 2. Chemokine binding, as measured by flow cytometry on wild type, mutant 27,
and complemented strains. A. CCL28 binding. Mutant 27, rfaD+, and rfaDF+ show
significantly higher binding than the wild type. rfaDFC+ restores wild type binding.
*= p< 0.01 compared to the wild type. B. The same pattern holds true for CCL25 binding,
another antimicrobial chemokine. += p> 0.01 compared to Mutant 27. Bars represent
standard error of the mean. n= 3 for both experiments.
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Percent viable

A.

BSA

C.

CCL28

Total number of cells counted

B.

*

*
BSA

E.

CCL28

Number of PI positive cells

D.

*

Figure 3. CCL28 killing assays. A. Overall survival. rfaDFC+ shows wild type resistance
while mutant 27 and rfaD+ and rfaDF+ strains show reduced survival compared to the
wild type. *= p< 0.01 B. Total cells counted in BSA (negative) controls. C. Total cells
counted when treated with 0.4 nM CCL28. *= p< 0.01 compared to the wild type. D.
Number of propidium iodide (PI) positive cells in BSA controls. E. PI positive cells,
CCL28 treated (0.4 nM). Bars represent standard error. n= 3 for all experiments.
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T= 0 hours

B.

Percent survival

A.

T= 2 hours

*
D.

Total cells counted

C.

*

F.

PI positive cells

E.

*

Figure 4. Polymyxin dilution killing assays. Overall survival at 0 hours (A) or 2 hours
(B). *= p< 0.01 between Mutant 27 and wild type through the 1:4000 dilution. Total cells
counted, 0 hours (C) and 2 hours (D). *= p< 0.01 between 27 and wild type through
1:8000 . PI positive cells, 0 hours (E) and 2 hours (F). *= p< 0.01 between 27 and wild
type through 1:4000. Bars represent standard error. n= 3 for all experiments.
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Figure 5. Relative gene expression in mutant 27 and complemented strains. Despite not
showing complementation of the mutant phenotype, mutant 27 shows relatively high
expression of all 3 genes within the rfaDFC operon. The complete operon in the
“forward” direction shows high expression of all 3 genes, as expected. The “reverse”
operon, surprisingly, shows high rfaD expression but low rfaF and rfaC expression. Bars
represent standard error. n= 5 except for * n= 2.
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Figure 6. Growth curve over 5 hours. Bacterial growth is shown as fold increase
compared to the initial cell count at 0 hours. There is a slight difference in growth of the
mutant 27 and the wild type at 5 hours. Bars represent standard error. n= 3.
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27

rfaD+

WT

rfaDF+

rfaDFC+

Figure 7. Cultures grown to mid‐logarithmic phase plated on TSA show no obvious
difference in colony shape or morphology after growth overnight at room temperature.
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Figure 8. Comparison of average size as measured from SEM images. Mutant 27 is
significantly different in size, statistically (p= 0.035), but not functionally, from the wild
type. Bars represent standard error; wild type, n= 228, mutant 27, n= 301.
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A.

B.

Figure 9. A. Y. pseudotuberculosis IP 32953 bacteria (wild type). B Mutant 27 bacteria.
Sample preparation was performed as described in the text.
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Figure 10. Predicted core structure for Mutant 27 (ΔrfaD). D, D‐ heptose can be used as
a substrate for the heptosyltransferases encoded by rfaF and rfaC, though with reduced
activity [85]. In Y. pseudotuberculosis, O‐units are added to the second heptose unit [122].
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1

2

3

4

5

6

7

O‐ antigen

Lipid A + core oligosaccharide
Lipid A

Figure 11. LPS analysis. Mutant 27 (lane 2) shows no O‐ antigen expression and the
presence of a bright, fast‐ migrating band. Addition of the complementation plasmids
(lanes 3‐5) shows that with each successive gene, the fast‐ migrating band grows
dimmer, the band representing lipid A plus the normal core grows brighter and the
O‐ antigen band increases. As expected, neither Y. pseudotuberculosis grown at 37°C or Y.
pestis shows O‐ antigen expression (lanes 6‐7). Lane 1‐ Wild type Y. pseudotuberculosis IP
32953 (grown at 25°C). Lane 2‐ Mutant 27. Lane 3‐ rfaD+ complement. Lane 4‐ rfaDF+
complement. Lane 5‐ rfaDFC+ complement. Lane 6‐ Wild type Y. pseudotuberculosis
grown at 37°C. Lane 7‐ Y. pestis KIM6.
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